MOHIT BANSAL

Vertex non-opioid painkiller meets main goal in late-stage trials

The company plans to file for U.S. approval by mid-2024 for the drug, which works by blocking pain signals at its origin before they reach the brain. If approved, it could achieve annual sales of more than $5 billion, according to analysts.